Jacqueline Magers
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jacqueline Magers has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Pablo Jose Sanchez
Nationwide Children's Hospital, The Ohio State University College of Medicine , Columbus, Ohio
6 shared publications - Pavel Prusakov
Department of Pharmacy, Nationwide Children’s Hospital, Columbus, USA
5 shared publications Richard Moraille
Central Ohio Newborn Medicine, Columbus, USA
5 shared publications- Concepción de Alba Romero
Department of Nutrition and Food Science, Complutense University of Madrid, 28040 Madrid, Spain
4 shared publications Anthony R. Theile
Central Ohio Newborn Medicine, Columbus, USA
3 shared publicationsNatalie O. White
Pediatrix Medical Group of Ohio, Columbus, USA
3 shared publications
Latest Publications
- Open Access
- 29 April 2026
- Published by Springer Nature in Journal of Perinatology
- Vol. 46 (5) , 754-760
Urinary tract infection in the neonatal intensive care unit
Objective: To determine adherence and safety of a diagnostic (culture, urinalysis) and therapeutic (5-day antibiotic course with a time-out) guideline for urinary tract infection (UTI) in the Neonatal Intensive Care Unit Study design: Prospective surveillance of non-bacteremic UTIs from 11/2020-12/2022. Safety outcomes were defined by re-initiation of antibiotics within 7 days for a subsequent UTI due to the same organism and overall and UTI-related mortality. Results: 77 infants received treatment for 93 UTIs with 77% (72/93) adherence to diagnostic criteria; 90% (82/91) of infants received ≤6 days of definitive treatment (median [IQR] antibiotic duration 5 [5–6] days). Antibiotics were restarted within 7 days for a recurrent (same organism) UTI in 1/91 (1%) UTIs. Mortality was 4% (4/93); none were due to UTI. Conclusion: Adherence to diagnostic UTI criteria was 77%. 90% of infants received short course treatment that was associated with a 1% failure rate. No safety concern was identified.
- 29 April 2026
- Published by Springer Nature in Journal of Perinatology
- Vol. 46 (5) , 754-760
Open AccessUrinary tract infection in the neonatal intensive care unit
Objective: To determine adherence and safety of a diagnostic (culture, urinalysis) and therapeutic (5-day antibiotic course with a time-out) guideline for urinary tract infection (UTI) in the Neonatal Intensive Care Unit Study design: Prospective surveillance of non-bacteremic UTIs from 11/2020-12/2022. Safety outcomes were defined by re-initiation of antibiotics within 7 days for a subsequent UTI due to the same organism and overall and UTI-related mortality. Results: 77 infants received treatment for 93 UTIs with 77% (72/93) adherence to diagnostic criteria; 90% (82/91) of infants received ≤6 days of definitive treatment (median [IQR] antibiotic duration 5 [5–6] days). Antibiotics were restarted within 7 days for a recurrent (same organism) UTI in 1/91 (1%) UTIs. Mortality was 4% (4/93); none were due to UTI. Conclusion: Adherence to diagnostic UTI criteria was 77%. 90% of infants received short course treatment that was associated with a 1% failure rate. No safety concern was identified.
- Open Access
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
1659. Prokinetic Antibiotic Agents in the Neonatal Intensive Care Unit: Ripe for Antibiotic Stewardship Efforts!
Intolerance to enteral nutrition among infants in the neonatal intensive care unit (NICU) may lead to the use of prokinetic agents to improve gastric emptying and feeding tolerance. Two such oral prokinetic agents are erythromycin and amoxicillin-clavulanate that have been used in cases of dysmotility due to intestinal failure. However, dosing strategies vary and the recommended duration of therapy has not been determined. Moreover, the use of these oral antibiotics in the NICU may fall under the radar of neonatal antimicrobial stewardship programs. Our objective was to quantify their use in the Level 4 outborn NICU at Nationwide Children’s Hospital, Columbus, OH in order to inform antibiotic stewardship efforts. This was a retrospective cohort study of all infants who received enteral erythromycin or amoxicillin-clavulanate in the NICU. The number of doses of each antibiotic was obtained from the Nationwide Children’s Hospital Pharmacy database. Pertinent clinical, laboratory, and outcome data were obtained. From January 1, 2022 to April 30, 2023, 15 infants in the NICU received ≥1 dose of erythromycin ethylsuccinate and 19 infants received ≥1 dose of amoxicillin-clavulanate enterally. Erythromycin was always used to improve motility while amoxicillin-clavulanate served as a prokinetic agent in 53% of infants in whom it was prescribed. Demographics and reason for initiation are provided in Table 1. The median (IQR) doses per patient for erythromycin was 64 (28, 125; dosing interval varied from every 6 to every 8 hours) and for amoxicillin-clavulanate was 50 (9, 105) doses per patient (majority of doses were given on a BID schedule). Enteral erythromycin and amoxicillin-clavulanate have not been the target of antimicrobial stewardship programs. These antibiotics may contribute to dysbiosis and adverse events in NICU infants. An automatic stop time with a time-out when ordered in the electronic health record may be a viable strategy to reduce overutilization of these antibiotics. Pavel Prusakov, PharmD, Merck & Co: Grant/Research Support|Merck & Co: Employee Michael Storey, PharmD, MS, CSL Behring: Advisor/Consultant|Sarepta Therapeutics: Advisor/Consultant
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
Open Access1659. Prokinetic Antibiotic Agents in the Neonatal Intensive Care Unit: Ripe for Antibiotic Stewardship Efforts!
Intolerance to enteral nutrition among infants in the neonatal intensive care unit (NICU) may lead to the use of prokinetic agents to improve gastric emptying and feeding tolerance. Two such oral prokinetic agents are erythromycin and amoxicillin-clavulanate that have been used in cases of dysmotility due to intestinal failure. However, dosing strategies vary and the recommended duration of therapy has not been determined. Moreover, the use of these oral antibiotics in the NICU may fall under the radar of neonatal antimicrobial stewardship programs. Our objective was to quantify their use in the Level 4 outborn NICU at Nationwide Children’s Hospital, Columbus, OH in order to inform antibiotic stewardship efforts. This was a retrospective cohort study of all infants who received enteral erythromycin or amoxicillin-clavulanate in the NICU. The number of doses of each antibiotic was obtained from the Nationwide Children’s Hospital Pharmacy database. Pertinent clinical, laboratory, and outcome data were obtained. From January 1, 2022 to April 30, 2023, 15 infants in the NICU received ≥1 dose of erythromycin ethylsuccinate and 19 infants received ≥1 dose of amoxicillin-clavulanate enterally. Erythromycin was always used to improve motility while amoxicillin-clavulanate served as a prokinetic agent in 53% of infants in whom it was prescribed. Demographics and reason for initiation are provided in Table 1. The median (IQR) doses per patient for erythromycin was 64 (28, 125; dosing interval varied from every 6 to every 8 hours) and for amoxicillin-clavulanate was 50 (9, 105) doses per patient (majority of doses were given on a BID schedule). Enteral erythromycin and amoxicillin-clavulanate have not been the target of antimicrobial stewardship programs. These antibiotics may contribute to dysbiosis and adverse events in NICU infants. An automatic stop time with a time-out when ordered in the electronic health record may be a viable strategy to reduce overutilization of these antibiotics. Pavel Prusakov, PharmD, Merck & Co: Grant/Research Support|Merck & Co: Employee Michael Storey, PharmD, MS, CSL Behring: Advisor/Consultant|Sarepta Therapeutics: Advisor/Consultant
- 12 July 2023
- Published by Springer Nature in Journal of Perinatology
- Vol. 43 (9) , 1145-1151
Short-course antibiotic therapy for pneumonia in the neonatal intensive care unit
Objective To determine the adherence and safety outcomes of a 5-day antibiotic course with a “time-out” for treatment of “blood culture-negative” pneumonia in the NICU. Study design Prospective surveillance of all infants diagnosed with pneumonia at 7 NICUs from 8/2020-12/2021. Safety outcomes were defined a priori by re-initiation of antibiotic therapy within 14 days after discontinuation and overall and sepsis-related mortality. Results 128 infants were diagnosed with 136 episodes of pneumonia; 88% (n = 119) were treated with 5 days of definitive antibiotic therapy. Antibiotics were restarted within 14 days in 22 (16%) of the 136 pneumonia episodes. However, only 3 (3%) of the 119 episodes of pneumonia treated for 5 days had antibiotics restarted for pneumonia. Mortality was 5% (7/128); 5 of the 7 deaths were assessed as sepsis-related. Conclusion Adherence to the 5-day definitive antibiotic treatment for “culture-negative” pneumonia was high and the intervention seemed safe.
- 12 July 2023
- Published by Springer Nature in Journal of Perinatology
- Vol. 43 (9) , 1145-1151
Short-course antibiotic therapy for pneumonia in the neonatal intensive care unit
Objective To determine the adherence and safety outcomes of a 5-day antibiotic course with a “time-out” for treatment of “blood culture-negative” pneumonia in the NICU. Study design Prospective surveillance of all infants diagnosed with pneumonia at 7 NICUs from 8/2020-12/2021. Safety outcomes were defined a priori by re-initiation of antibiotic therapy within 14 days after discontinuation and overall and sepsis-related mortality. Results 128 infants were diagnosed with 136 episodes of pneumonia; 88% (n = 119) were treated with 5 days of definitive antibiotic therapy. Antibiotics were restarted within 14 days in 22 (16%) of the 136 pneumonia episodes. However, only 3 (3%) of the 119 episodes of pneumonia treated for 5 days had antibiotics restarted for pneumonia. Mortality was 5% (7/128); 5 of the 7 deaths were assessed as sepsis-related. Conclusion Adherence to the 5-day definitive antibiotic treatment for “culture-negative” pneumonia was high and the intervention seemed safe.
- Open Access
- 27 April 2023
- Published by Springer Nature in Research Square
Short-Course Antibiotic Therapy for Pneumonia in the Neonatal Intensive Care Unit
Objective. To determine the adherence and safety outcomes of a 5-day antibiotic course with a “time-out” for treatment of “blood culture-negative” pneumonia in the NICU Study design. Prospective surveillance of all infants diagnosed with pneumonia at 7 NICUs from 8/2020-12/2021. Safety outcomes were defined a priori by re-initiation of antibiotic therapy within 14 days after discontinuation and overall and sepsis-related mortality. Results. 128 infants were diagnosed with 136 episodes of pneumonia; 88% (n=119) were treated with 5 days of definitive antibiotic therapy. Antibiotics were restarted within 14 days in 22 (16%) of the 136 pneumonia episodes. Mortality was 5% (7/128); 5 of the 7 deaths were assessed as sepsis-related. There was no difference in the combined safety outcomes of antibiotic restart or mortality between ≤5 and 6-20 days of definitive antibiotic treatment. Conclusion. Adherence to the 5-day definitive antibiotic treatment for “culture-negative” pneumonia was high and the intervention seemed safe.
- 27 April 2023
- Published by Springer Nature in Research Square
Open AccessShort-Course Antibiotic Therapy for Pneumonia in the Neonatal Intensive Care Unit
Objective. To determine the adherence and safety outcomes of a 5-day antibiotic course with a “time-out” for treatment of “blood culture-negative” pneumonia in the NICU Study design. Prospective surveillance of all infants diagnosed with pneumonia at 7 NICUs from 8/2020-12/2021. Safety outcomes were defined a priori by re-initiation of antibiotic therapy within 14 days after discontinuation and overall and sepsis-related mortality. Results. 128 infants were diagnosed with 136 episodes of pneumonia; 88% (n=119) were treated with 5 days of definitive antibiotic therapy. Antibiotics were restarted within 14 days in 22 (16%) of the 136 pneumonia episodes. Mortality was 5% (7/128); 5 of the 7 deaths were assessed as sepsis-related. There was no difference in the combined safety outcomes of antibiotic restart or mortality between ≤5 and 6-20 days of definitive antibiotic treatment. Conclusion. Adherence to the 5-day definitive antibiotic treatment for “culture-negative” pneumonia was high and the intervention seemed safe.
- 22 February 2023
- Published by Springer Nature in Journal of Perinatology
- Vol. 43 (6) , 741-745
Short-course empiric antibiotic therapy for possible early-onset sepsis in the NICU
Objective On 2/2019, the Neonatal Antimicrobial Stewardship Program at Nationwide Children’s Hospital recommended reducing empirical antibiotic therapy for early-onset sepsis (EOS) from 48 to 24 hours with a TIME-OUT. We describe our experience with this guideline and assess its safety. Methods Retrospective review of newborns evaluated for possible EOS at 6 NICUs from 12/2018-7/2019. Safety endpoints were re-initiation of antibiotics within 7 days after discontinuation of the initial course, positive bacterial blood or cerebrospinal fluid culture in the 7 days after antibiotic discontinuation, and overall and sepsis-related mortality. Result Among 414 newborns evaluated for EOS, 196 (47%) received a 24 hour rule-out sepsis antibiotic course while 218 (53%) were managed with a 48 hour course. The 24-hour rule-out group were less likely to have antibiotics re-initiated and did not differ in the other predefined safety endpoints. Conclusion Antibiotic therapy for suspected EOS may be discontinued safely within 24 hours.
- 22 February 2023
- Published by Springer Nature in Journal of Perinatology
- Vol. 43 (6) , 741-745
Short-course empiric antibiotic therapy for possible early-onset sepsis in the NICU
Objective On 2/2019, the Neonatal Antimicrobial Stewardship Program at Nationwide Children’s Hospital recommended reducing empirical antibiotic therapy for early-onset sepsis (EOS) from 48 to 24 hours with a TIME-OUT. We describe our experience with this guideline and assess its safety. Methods Retrospective review of newborns evaluated for possible EOS at 6 NICUs from 12/2018-7/2019. Safety endpoints were re-initiation of antibiotics within 7 days after discontinuation of the initial course, positive bacterial blood or cerebrospinal fluid culture in the 7 days after antibiotic discontinuation, and overall and sepsis-related mortality. Result Among 414 newborns evaluated for EOS, 196 (47%) received a 24 hour rule-out sepsis antibiotic course while 218 (53%) were managed with a 48 hour course. The 24-hour rule-out group were less likely to have antibiotics re-initiated and did not differ in the other predefined safety endpoints. Conclusion Antibiotic therapy for suspected EOS may be discontinued safely within 24 hours.
- Open Access
- 13 September 2022
- Published by Springer Nature in Research Square
Short-Course Empiric Antibiotic Therapy for Possible Early-Onset Sepsis in the NICU
Objective. On 2/2019, the Neonatal Antimicrobial Stewardship Program at Nationwide Children’s Hospital recommended reducing empirical antibiotic therapy for early-onset sepsis (EOS) from 48 to 24 hours with a TIME-OUT. We describe our experience with this guideline and assess its safety. Methods. Retrospective review of all newborns evaluated for possible EOS at Result. Among 414 newborns evaluated for EOS, 196 (47%) received a 24 hour rule-out sepsis antibiotic course while 218 (53%) were managed with a 48 hour course. Infants in the two groups did not differ in the predefined safety endpoints. Conclusion. Antibiotic therapy for suspected EOS may be discontinued safely within 24 hours.
- 13 September 2022
- Published by Springer Nature in Research Square
Open AccessShort-Course Empiric Antibiotic Therapy for Possible Early-Onset Sepsis in the NICU
Objective. On 2/2019, the Neonatal Antimicrobial Stewardship Program at Nationwide Children’s Hospital recommended reducing empirical antibiotic therapy for early-onset sepsis (EOS) from 48 to 24 hours with a TIME-OUT. We describe our experience with this guideline and assess its safety. Methods. Retrospective review of all newborns evaluated for possible EOS at Result. Among 414 newborns evaluated for EOS, 196 (47%) received a 24 hour rule-out sepsis antibiotic course while 218 (53%) were managed with a 48 hour course. Infants in the two groups did not differ in the predefined safety endpoints. Conclusion. Antibiotic therapy for suspected EOS may be discontinued safely within 24 hours.
- 25 June 2022
- Published by Springer Nature in Journal of Perinatology
- Vol. 42 (12) , 1644-1648
Effects of prophylactic indomethacin on intraventricular hemorrhage and adverse outcomes in neonatal intensive care unit
Objective To identify the relationship between prophylactic indomethacin (PI) administration and incidence of intraventricular hemorrhage. Study design A retrospective analysis of extremely premature infants p = 0.68). The rate of rise of serum creatinine from baseline to day of life four was significantly higher in the PI group (0.14 mg/dl PI and 0.03 mg/dl control, p < 0.001). Conclusion PI was not associated with any benefit in prevention of IVH, but is associated with adverse effects including acute rise in creatinine.
- 25 June 2022
- Published by Springer Nature in Journal of Perinatology
- Vol. 42 (12) , 1644-1648
Effects of prophylactic indomethacin on intraventricular hemorrhage and adverse outcomes in neonatal intensive care unit
Objective To identify the relationship between prophylactic indomethacin (PI) administration and incidence of intraventricular hemorrhage. Study design A retrospective analysis of extremely premature infants p = 0.68). The rate of rise of serum creatinine from baseline to day of life four was significantly higher in the PI group (0.14 mg/dl PI and 0.03 mg/dl control, p < 0.001). Conclusion PI was not associated with any benefit in prevention of IVH, but is associated with adverse effects including acute rise in creatinine.